Portfolio

Previa Medical, a deeptech startup specializing in the development of predictive medicine tools.

Previa has developed SEPSI-SCORE©, an artificial intelligence solution specialized in the early detection of sepsis, certified as a medical device in 2021. The platform alerts healthcare professionals up to 48 hours before the first symptoms. Integrated into the hospital’s business software, it analyzes patient medical records in real-time. It allows healthcare professionals to identify risks accurately, start the care protocol as quickly as possible, and thus increase patient survival.

M2care invests financially and humanly during the Pre-Seed round, aiming to achieve regulatory and clinical milestones, prepare the company’s commercial development, and develop new indications.

The brain is protected from pathogens and certain molecules by the blood-brain barrier, complicating the development of effective drugs for diseases like brain cancers.

TheraSonic, a startup resulting from 15 years of research at CEA Saclay and CNRS, develops a medical device using transcranial focused ultrasound to make this barrier permeable to drugs and allow their delivery. This non-invasive medical device, combining a robotic arm and a neuronavigation system, precisely targets areas of the brain, opening new perspectives for treating brain metastases. A patented ultrasonic dosimetry system ensures the device’s safety.

Involved for several months alongside the scientific team, M2care invests financially and humanly in the creation of TheraSonic, aiming to conduct a first human study by 2025.

To be discovered at the end of 2024.